The Alzheimer's Drug Discovery Foundation (ADDF) has
been a source of several peer-reviewed grants supporting PTX technology and its
peer-reviewed Biotechnology Program maintains scientific oversight and an equity
position in PTX.

The Alzheimer Association  Part-the-Cloud Program has provided peer-reviewed funding in support of the successful completion of the PTX LM11A-31 phase 1 safety trial.

 In 2016 PharmatrophiX was awarded a peer-reviewed NIH Alzheimer’s Disease Pilot Clinical Trials Award ($4.5M direct funding) to provide support for its current phase 2a trial. The principle investigator is Dr. Manfred Windisch, CEO and President, Neuroscios, a PharmatrophiX partner and the co-investigators are Drs. Niels Andreasen and Agneta Nordberg at the Karolinska Institute in Stockholm.